Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0241
NEWS & VIEWS
|
Everolimus added to aromatase inhibitors for improving hormone-receptor-positive breast cancer outcomes.
|
Eleftheria Ignatiadou, MD.
|
Affiliation: Dr. Eleftheria Ignatiadou, Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.
E-mail: eliaign@yahoo.gr |
Since there is no abstract available we provide the first paragraph.
Activation of the mammalian target of rapamycin (mTOR) intracellular signalling pathway can be one of the causes to endocrine therapy resistance in breast cancer. Everolimus, a mTOR inhibitor, has shown antitumor activity in previous studies. Baselga and colleagues [1] report now in NEJM the results of a phase 3 randomized trial in which everolimus was added to exemestane in patients with hormone-receptor-positive advanced breast cancer. The potential to overcome resistance to aromatase inhibitor by adding everolimus in standard therapy of breast is discussed.
(Citation: Gastric & Breast Cancer
2012; 11(3): 163-165).
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
